996
Participants
Start Date
September 7, 2018
Primary Completion Date
January 17, 2019
Study Completion Date
June 11, 2019
MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A)
Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm
Licensed GSK MenACWY vaccine (Menveo)
Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm
GSK Investigational Site, Blacktown
GSK Investigational Site, Kanwal
GSK Investigational Site, Leuven
GSK Investigational Site, Melbourne
GSK Investigational Site, Sherwood
GSK Investigational Site, Gold Coast
GSK Investigational Site, Adelaide
GSK Investigational Site, Murdoch
GSK Investigational Site, Ghent
GSK Investigational Site, Berlin
GSK Investigational Site, Genoa
GSK Investigational Site, Hamburg
GSK Investigational Site, Conegliano - Treviso
GSK Investigational Site, Essen
GSK Investigational Site, Goch
GSK Investigational Site, Mainz
GSK Investigational Site, Chieti
GSK Investigational Site, Massafra (TA)
GSK Investigational Site, Würzburg
GSK Investigational Site, Melbourne
GSK Investigational Site, Victoria
GSK Investigational Site, Halifax
GSK Investigational Site, Truro
GSK Investigational Site, Brampton
GSK Investigational Site, London
GSK Investigational Site, Toronto
GSK Investigational Site, Mirabel
GSK Investigational Site, Pointe-Claire
GSK Investigational Site, Québec
GSK Investigational Site, Sherbrooke
Lead Sponsor
GlaxoSmithKline
INDUSTRY